March 15, 2026
Research
NMN & Vision: How NAD+ Protects Your Eyes as You Age
March 26, 2026 · 9 min read
Your eyes are among the most metabolically demanding organs in your body. The retina — a thin layer of tissue at the back of your eye that converts light into the neural signals your brain interprets as vision — consumes more oxygen per gram than the brain itself. This extraordinary metabolic demand makes the retina uniquely vulnerable to one thing: energy decline.
And that's exactly what happens as you age. NAD+ levels in the retina fall progressively, starving photoreceptor cells of the energy they need to function and survive. The result? A gradual decline in visual acuity, increased susceptibility to degenerative eye diseases, and in severe cases, irreversible vision loss.
But an emerging body of peer-reviewed research — from Harvard Medical School, Washington University, Keio University, Karolinska Institutet, and others — is revealing something remarkable: NMN (Nicotinamide Mononucleotide) can restore NAD+ levels in the retina, protect photoreceptor cells from degeneration, and preserve visual function.
The Retina: A Metabolic Powerhouse Under Threat
To understand why NAD+ matters so much for your eyes, you need to understand the retina's unique biology. The neurosensory retina is one of the most metabolically active tissues in the entire body. Photoreceptors — the rod and cone cells responsible for light detection — are terminally differentiated neurons that cannot regenerate once lost. Despite being non-dividing, these cells have enormous energy demands throughout their entire lifespan, and they face constant light-induced oxidative stress simply by performing their primary function of transducing light into neural signals.
NAD+ sits at the centre of this energy system. It is both an essential coenzyme — functioning as an electron carrier in glycolysis and the Krebs cycle — and a critical cosubstrate for NAD+-consuming enzymes including sirtuins (SIRT1, SIRT3, SIRT5), PARPs (which repair DNA damage), and CD38. Every one of these processes is essential for keeping photoreceptors alive and functioning.
The problem is that NAD+ levels in the retina decline with age. And when they do, the consequences are severe.
NAD+ Biosynthesis Is Essential for Vision
The most direct evidence that NAD+ is non-negotiable for vision comes from a landmark study at Washington University School of Medicine. Researchers led by Dr. Rajendra S. Apte demonstrated that when the gene for NAMPT — the rate-limiting enzyme in the body's primary NAD+ production pathway — was specifically deleted from rod or cone photoreceptors in mice, the result was retinal degeneration and vision loss.
Study 1: NAMPT-Mediated NAD+ Biosynthesis Is Essential for Vision
When NAMPT was deleted from photoreceptors, cells could no longer produce NAD+ through the salvage pathway — the predominant route for NAD+ synthesis in mammals. Without NAD+, photoreceptors experienced catastrophic metabolic dysfunction and died. Crucially, the researchers found that NMN administration rescued vision — restoring photoreceptor function and survival even after the genetic pathway for NAD+ production was removed.
The study also revealed a broader finding: retinal NAD+ deficiency was an early feature of multiple models of retinal disease, including light-induced degeneration, streptozotocin-induced diabetic retinopathy, and age-associated retinal dysfunction. This suggests that NAD+ decline is not just associated with one type of eye disease — it may be a unifying mechanism across many of them.
Source: Lin, J.B., Kubota, S., Ban, N., et al. "NAMPT-mediated NAD+ biosynthesis is essential for vision in mice." Cell Reports, 2016. Washington University School of Medicine.
This finding is profound. It tells us that NAD+ isn't just helpful for vision — it is essential. Without it, photoreceptors die. And NMN can provide the NAD+ they need to survive.
NMN Protects Photoreceptors in Retinal Degeneration
Building on this foundation, a research team from Harvard Medical School — including David Sinclair's lab at the Paul F. Glenn Center for Biology of Aging Research — investigated NMN's protective effects in a photoreceptor degenerative model of retinal detachment, one of the most common causes of permanent vision loss.
Study 2: NMN in a Photoreceptor Degenerative Model (Harvard Medical School)
The results were striking. NMN administration after retinal detachment reduced photoreceptor cell death by up to 71% at the 500 mg/kg dose (p<0.001). It also significantly reduced infiltrating inflammatory macrophages (CD11b+ cells), counteracted excessive oxidative stress, and preserved outer nuclear layer (ONL) thickness — the retinal layer where photoreceptors reside.
Mechanistically, NMN increased retinal NAD+ levels to approximately 120% above baseline and upregulated SIRT1 expression. The researchers further demonstrated that the protection was mediated in part through the SIRT1/HO-1 signalling pathway, which counteracts oxidative damage. In cell culture studies, blocking SIRT1 activity abolished NMN's protective effect, confirming SIRT1 as a key mediator.
Source: Chen, X., Amorim, J.A., Moustafa, G.A., et al. "Neuroprotective effects and mechanisms of action of nicotinamide mononucleotide (NMN) in a photoreceptor degenerative model of retinal detachment." AGING, 2020, Vol. 12, No. 24. Harvard Medical School / Massachusetts Eye and Ear.
NMN Prevents Retinal Damage from Ischemia
Retinal ischemia — when blood flow to the retina is temporarily restricted and then restored — causes severe damage through reactive oxygen species and inflammation. It's a mechanism involved in diabetic retinopathy, retinal vein occlusion, and glaucoma. A 2022 study at Keio University School of Medicine tested whether NMN could prevent this kind of damage.
Study 3: NMN Prevents Retinal Dysfunction in Ischemia/Reperfusion Injury
Mice were given NMN injections before and after retinal ischemia/reperfusion injury. The treatment significantly preserved retinal function (measured by electroretinography b-wave amplitude) and markedly reduced inflammatory cell infiltration in the ischemic retina. In cell culture, NMN reduced oxidative stress-induced photoreceptor cell death (p<0.001) and upregulated the antioxidant genes Nrf2 and Hmox-1 — both critical for cellular defence against oxidative damage.
Source: Lee, D., Tomita, Y., Miwa, Y., et al. "Nicotinamide Mononucleotide Prevents Retinal Dysfunction in a Mouse Model of Retinal Ischemia/Reperfusion Injury." International Journal of Molecular Sciences, 2022, 23, 11228. Keio University School of Medicine.
NAD+ and Glaucoma: Protecting the Optic Nerve
Glaucoma is the leading cause of irreversible blindness worldwide, affecting approximately 80 million people. It destroys retinal ganglion cells — the neurons whose axons converge to form the optic nerve, transmitting visual information from the eye to the brain. Once these cells are lost, the damage is permanent. Currently, the only available treatments target intraocular pressure, but 42% of treated glaucoma patients still progress to blindness in at least one eye.
A major 2021 study published in Redox Biology, involving researchers from Karolinska Institutet, Cardiff University, and the University of Melbourne, demonstrated that NAD+ supplementation provides robust neuroprotection in glaucoma.
Study 4: Nicotinamide Provides Neuroprotection in Glaucoma
Using the DBA/2J mouse model of glaucoma, researchers demonstrated that NAD declines in the retina in an age-dependent manner, rendering retinal ganglion cells susceptible to pressure-related stress. NAM (nicotinamide, an NAD+ precursor) supplementation was robustly protective against retinal ganglion cell neurodegeneration, preserving mitochondrial function and preventing metabolic dysfunction.
The study also found that glaucoma patients have systemically low levels of NAM in their blood, supporting the hypothesis that pathogenically low NAD+ contributes to glaucoma susceptibility. These findings have driven the initiation of clinical trials investigating nicotinamide as a treatment for glaucoma in humans (NCT03797469).
Source: Tribble, J.R., Otmani, A., Sun, S., et al. "Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunction." Redox Biology, 43, 101988, 2021. Karolinska Institutet / Cardiff University / University of Melbourne.
NAD+ Decline in the Ageing Retina: A Comprehensive Review
A comprehensive 2020 review published in Oxidative Medicine and Cellular Longevity by researchers at Augusta University pulled together the existing evidence on NAD+ metabolism in the retina. Their conclusions paint a clear picture:
Study 5: Implications of NAD+ Metabolism in the Aging Retina
- NAD+ levels in the human body are maintained at approximately 3 grams in the average healthy adult, but decline progressively with age
- This age-related NAD+ decrease has been linked strongly to processes relevant to normal ageing and to age-related diseases including retinal degeneration
- The enzyme NAMPT — essential for NAD+ production — has been shown to be of "paramount importance" in the ocular environment
- Alterations in circulating NAMPT levels correlate strongly with risk for retinal vein occlusions
- Mutations in NMNAT1, another NAD+ biosynthetic enzyme, cause Leber congenital amaurosis (LCA9) — a severe genetic form of childhood blindness
- When NAD+ production is inhibited in human retinal pigment epithelial (RPE) cells, an early senescent phenotype is promoted — the cells age prematurely
- Supplementation with NAD+ precursors has been shown to improve NAD+ levels in aged tissues and protect against ageing and age-related disease
Source: Jadeja, R.N., Thounaojam, M.C., Bartoli, M., Martin, P.M. "Implications of NAD+ Metabolism in the Aging Retina and Retinal Degeneration." Oxidative Medicine and Cellular Longevity, 2020. Augusta University.
The Bigger Picture: Why Your Eyes Need NAD+
Taken together, these five studies — spanning Harvard, Washington University, Keio University, Karolinska Institutet, and Augusta University — reveal a consistent and compelling picture:
The Problem
- NAD+ declines in the retina with age
- Photoreceptors starve without NAD+
- Oxidative stress overwhelms defences
- Mitochondrial dysfunction accelerates
- Retinal ganglion cells degenerate
The NMN Solution
- Restores NAD+ levels to 120%+ baseline
- Reduces photoreceptor death by up to 71%
- Activates SIRT1 protective pathways
- Upregulates antioxidant gene expression
- Suppresses retinal inflammation
The retina is an extension of your brain — it's neural tissue with extraordinary metabolic demands. When NAD+ falls, the retina is among the first tissues to suffer. NMN provides a direct, efficient route to replenish the NAD+ your retina needs to maintain photoreceptor health, defend against oxidative stress, support mitochondrial function, and potentially slow or prevent the progression of age-related eye diseases.
While human clinical trials specifically for NMN and retinal health are still in their early stages, the preclinical evidence from multiple world-leading institutions is remarkably consistent. The message is clear: NAD+ is essential for vision, and NMN is one of the most effective ways to restore it.
References
- Lin, J.B., Kubota, S., Ban, N., Yoshida, M., Santeford, A., Sene, A., Nakamura, R., Zapata, N., Kubota, M., Tsubota, K., Yoshino, J., Imai, S., Apte, R.S. (2016). "NAMPT-mediated NAD+ biosynthesis is essential for vision in mice." Cell Reports, Washington University School of Medicine.
- Chen, X., Amorim, J.A., Moustafa, G.A., Lee, J.J., Yu, Z., Ishihara, K., Iesato, Y., Barbisan, P., Ueta, T., Togka, K.A., Lu, L., Sinclair, D.A., Vavvas, D.G. (2020). "Neuroprotective effects and mechanisms of action of nicotinamide mononucleotide (NMN) in a photoreceptor degenerative model of retinal detachment." AGING, Vol. 12, No. 24, pp. 24504+. Harvard Medical School / Massachusetts Eye and Ear.
- Lee, D., Tomita, Y., Miwa, Y., Shinojima, A., Ban, N., Yamaguchi, S., Nishioka, K., Negishi, K., Yoshino, J., Kurihara, T. (2022). "Nicotinamide Mononucleotide Prevents Retinal Dysfunction in a Mouse Model of Retinal Ischemia/Reperfusion Injury." International Journal of Molecular Sciences, 23, 11228. Keio University School of Medicine.
- Tribble, J.R., Otmani, A., Sun, S., Ellis, S.A., Cimaglia, G., Vohra, R., Joe, M., Lardner, E., Venkataraman, A.P., Dominguez-Vicent, A., et al. (2021). "Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunction." Redox Biology, 43, 101988. Karolinska Institutet / Cardiff University.
- Jadeja, R.N., Thounaojam, M.C., Bartoli, M., Martin, P.M. (2020). "Implications of NAD+ Metabolism in the Aging Retina and Retinal Degeneration." Oxidative Medicine and Cellular Longevity, 2020. Augusta University.
Continue Reading
March 26, 2026